Injection Site Reactions: Where Semaglutide and Tirzepatide Really Differ

These two drugs are not the same on this, and the gap is larger than almost anything else separating them. Semaglutide produced injection site reactions in 1.4% of patients against 1% on placebo — barely a difference.^[1] Tirzepatide runs 6% to 8% against 2%, rising with dose.^[2] If you are getting lumps and redness on one and did not on the other, that is not your technique.

The two drugs, side by side

The semaglutide label lists what counts as a reaction: itching, redness, inflammation, hardening of the tissue, and irritation.^[1] Those are local, they settle, and at 1.4% against 1% they are close to background.

Tirzepatide’s figures behave differently. They roughly triple from placebo at the lowest dose and then flatten — 6%, 8%, 8% — which is the same plateau pattern its gastrointestinal effects show. Getting through the first dose tends to predict the rest.

The serious reaction is a different thing entirely

A lump at the injection site and an allergic reaction to the drug are not two points on one scale, and conflating them is how people either panic about a bruise or ignore something that matters.

The semaglutide label carries serious hypersensitivity in its warnings: anaphylaxis and angioedema have been reported. If one occurs, the instruction is to stop the drug, treat promptly, and monitor until it resolves — and the drug then becomes contraindicated — for the molecule and for any of the excipients in it.^[1]

A prior serious reaction is not a caution to weigh. It is a contraindication.

What is ordinary

• A small red mark or mild itch for a day or two. Common with any subcutaneous injection, and on the label for both drugs.
• A firm lump under the skin — induration, in the label’s language. It is why every label asks for site rotation with each dose. Our rotation calendar tracks it, and where to inject covers technique.
• A small bruise, which is about the needle and the capillary it happened to meet, not the drug.

None of that needs treating. Rotating sites is the one thing that reliably helps, and it is asked for on the label precisely because repeatedly injecting the same spot is what produces persistent lumps.

If reactions are why you want to switch

That is a legitimate reason and the numbers support it in one direction: someone reacting on tirzepatide has a reasonable expectation of fewer local reactions on semaglutide, because 1.4% against 1% is close to nothing. The reverse is not true.

It is worth weighing against everything else that differs between them — effect size, cost, coverage, the other side effects. Our tirzepatide timeline and semaglutide timeline set out what each does on the scale, and switching itself has a dose-equivalence problem covered by the switch calculator. A sore spot where you inject is also a different thing from aches elsewhere in the body, which the trials counted separately.